Loading Calculator...
Please wait a moment
Please wait a moment
Analyze calcium-PTH relationships to diagnose parathyroid and calcium metabolism disorders
Calcium homeostasis is tightly regulated by parathyroid hormone (PTH), vitamin D, and calcitonin. PTH is secreted by the parathyroid glands in response to low serum calcium, acting on bone (increases resorption), kidney (increases calcium reabsorption and phosphate excretion), and indirectly on the intestine (via vitamin D activation) to raise calcium levels.
The calcium-PTH relationship is crucial for diagnosis. In primary hyperparathyroidism, autonomous PTH secretion causes hypercalcemia despite elevated PTH. In secondary hyperparathyroidism, PTH appropriately rises in response to hypocalcemia from vitamin D deficiency, CKD, or other causes. Understanding this relationship allows accurate diagnosis of calcium disorders.
Corrected calcium is essential when albumin is abnormal, as approximately 40% of serum calcium is protein-bound (mostly to albumin). Low albumin falsely lowers measured calcium; the correction formula estimates what the calcium would be at a normal albumin of 4.0 g/dL. Ionized calcium measurement provides a more direct assessment but is less commonly available.
Primary hyperparathyroidism is the most common cause of hypercalcemia in outpatients, typically caused by a single parathyroid adenoma (80%), hyperplasia of multiple glands (15-20%), or rarely parathyroid carcinoma (<1%). It's characterized by elevated calcium with inappropriately elevated or non-suppressed PTH.
Many patients are asymptomatic, discovered incidentally on routine labs. Symptomatic patients may experience "stones, bones, groans, and psychiatric overtones" - kidney stones, osteoporosis/bone pain, gastrointestinal symptoms, and neuropsychiatric manifestations. Chronic hypercalcemia can cause nephrocalcinosis, pancreatitis, and cardiovascular effects.
Management depends on severity and symptoms. Surgical parathyroidectomy is curative and recommended for symptomatic disease, age <50, calcium >1 mg/dL above normal, reduced bone density (T-score <-2.5), or renal involvement. Medical monitoring is appropriate for asymptomatic patients not meeting surgical criteria, with periodic assessment of calcium, bone density, and renal function.
Secondary hyperparathyroidism represents an appropriate physiologic response to hypocalcemia or factors that lower calcium. Vitamin D deficiency is the most common cause, as vitamin D is essential for intestinal calcium absorption. Low vitamin D leads to decreased calcium absorption, mild hypocalcemia, and compensatory PTH elevation.
Chronic kidney disease is another major cause, as failing kidneys cannot activate vitamin D (convert 25-OH-D to active 1,25-dihydroxy-D) and retain phosphate, both leading to hypocalcemia and PTH elevation. Over time, this can progress to tertiary hyperparathyroidism where the parathyroid glands become autonomous.
Treatment focuses on addressing the underlying cause. Vitamin D deficiency is treated with vitamin D supplementation (ergocalciferol or cholecalciferol), typically starting with higher doses for deficiency followed by maintenance. In CKD, treatment includes phosphate binders, active vitamin D analogs (calcitriol), and calcimimetics to control PTH.
Hypoparathyroidism, characterized by low calcium with inappropriately low PTH, most commonly results from iatrogenic parathyroid gland damage or removal during thyroid/neck surgery. Other causes include autoimmune destruction (isolated or as part of polyglandular syndromes), genetic disorders, infiltrative diseases, or severe magnesium deficiency.
Symptoms of hypocalcemia include neuromuscular irritability (paresthesias, tetany, Chvostek's and Trousseau's signs), seizures, prolonged QT interval on ECG, and in chronic cases, cataracts and calcification of basal ganglia. Severity correlates with both the degree of hypocalcemia and the rate of decline.
Treatment of chronic hypoparathyroidism requires calcium supplementation (1000-3000 mg elemental calcium daily in divided doses) and active vitamin D (calcitriol 0.25-2 mcg daily), as PTH is needed to activate vitamin D in the kidneys. The goal is to maintain calcium in the low-normal range to minimize hypercalciuria risk. Recombinant PTH is available for refractory cases.
Corrected calcium is calculated when albumin is abnormal (particularly low albumin in chronic illness, malnutrition, or liver disease). Ionized calcium directly measures the physiologically active form and is more accurate but less commonly available. Use ionized calcium when available in critically ill patients or when acid-base disorders are present, as pH affects protein binding.
FHH is a benign genetic condition caused by calcium-sensing receptor mutations, resulting in mild hypercalcemia with normal/mildly elevated PTH but characteristically low urine calcium (<100 mg/24h). It's important to distinguish from primary hyperparathyroidism as FHH doesn't require treatment. Calculate calcium/creatinine clearance ratio: <0.01 suggests FHH, >0.02 suggests primary hyperparathyroidism.
Vitamin D is essential for intestinal calcium absorption. When vitamin D is deficient, less calcium is absorbed from food, leading to mild hypocalcemia or low-normal calcium. The parathyroid glands sense this and appropriately secrete more PTH to maintain calcium levels by increasing bone resorption and renal calcium reabsorption. This is secondary hyperparathyroidism.
Normocalcemic hyperparathyroidism is characterized by consistently elevated PTH with normal calcium levels after excluding secondary causes (vitamin D deficiency, CKD, medications). It may represent early primary hyperparathyroidism. Workup includes optimizing vitamin D, 24-hour urine calcium (often elevated), and bone density assessment. Some patients progress to hypercalcemia; others remain stable.
CKD affects calcium metabolism through multiple mechanisms: decreased activation of vitamin D (kidneys convert 25-OH-D to active 1,25-dihydroxy-D), phosphate retention (binds calcium and stimulates PTH), and skeletal resistance to PTH. This leads to hypocalcemia, hyperphosphatemia, and elevated PTH (secondary hyperparathyroidism). Advanced CKD can progress to tertiary hyperparathyroidism with autonomous PTH secretion.
PTH-independent hypercalcemia (high calcium, low PTH) indicates non-parathyroid causes. Malignancy is most common (PTHrP from tumors, osteolytic metastases, multiple myeloma). Other causes include vitamin D intoxication, granulomatous diseases (sarcoidosis, TB), hyperthyroidism, immobilization, and medications (thiazides, lithium). The suppressed PTH represents appropriate negative feedback.
PTH promotes renal phosphate excretion by inhibiting phosphate reabsorption in the proximal tubule. In primary hyperparathyroidism with chronically elevated PTH, this leads to increased urinary phosphate loss and low serum phosphorus. The combination of hypercalcemia with hypophosphatemia is characteristic of primary hyperparathyroidism, helping distinguish it from other causes of hypercalcemia.
Severe symptomatic hypocalcemia (tetany, seizures, QT prolongation) requires urgent IV calcium replacement. Mild chronic hypocalcemia can be corrected gradually with oral supplements. For hypercalcemia, severity determines urgency: mild asymptomatic hypercalcemia can be evaluated outpatient, but calcium >14 mg/dL or severe symptoms (altered mental status, dehydration) requires hospitalization for IV fluids, possible calcitonin, bisphosphonates, or dialysis.